Search
Velsecorat
go.drugbank.com/drugs/DB16347InvestigationalVelsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients
Palucorcel
go.drugbank.com/drugs/DB17955InvestigationalDeveloped by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.
Josamycin
go.drugbank.com/drugs/DB01321InvestigationalA macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Curcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceuticalCurcuma xanthorrhiza oil is extracted from Curcuma xanthorrhiza Roxb., a member of the ginger family (Zingiberaceae) that is widely distributed in the region of Southeastern Asia . Curcuma xanthorrhiza is also known as Javanese Turmeric ...
Thrombomodulin Alfa
go.drugbank.com/drugs/DB05777ApprovedThrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting...
Methyl nicotinate
go.drugbank.com/drugs/DB13882ApprovedMethyl nicotinate is the methyl ester of DB00627 that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. The action of methyl nicotinate as a rubefacient is thou...
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
CMLVAX100
go.drugbank.com/drugs/DB05164ExperimentalIt is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Nitarsone
go.drugbank.com/drugs/DB11437ExperimentalVet approvedIt is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer.